Onduo

Onduo is a virtual care platform providing personalized care for chronic conditions using deep analytics, connected devices, and a care app. The company’s primary focus areas are 1) type 2 diabetes, 2) hypertension, 3) weight management, and 4) mental health. The company has access to Alphabet group’s advanced software to evaluate multiple data streams (digital phenotype).

Onduo’s care solution includes telemedicine visits, personalized insights on health risks and progress, integrated devices, tools, and education guidance for each of the focus areas. Further, members are provided with connected devices depending on the selected program—a blood glucose meter for diabetes, a bluetooth scale for weight loss, and a blood pressure cuff for hypertension.

In June 2024, Verily, Onduo’s founding entity and a subsidiary of Alphabet, introduced Lightpath, an AI-powered chronic care solution that will replace Onduo and offer personalized programs for diabetes and hypertension, including GLP-1 drug prescriptions, by 2026. The new platform will utilize AI and continuous glucose monitoring devices to tailor care to individual needs.

Key customers and partnerships

The company operates a B2B2C business model providing services to members via insurance providers and employers. In September 2021, the company partnered with Fitbit (owned by Google) to provide eligible members with Fitbit’s device, a wearable sensor, and access to its Fitbit Premium app as part of Onduo’s care solution to track activity, sleep, and stress levels.

Furthermore, in August 2022, the company partnered with digital musculoskeletal (chronic conditions affecting bones, joints, and muscles) care provider Sword Health . This partnership expanded Onduo’s care solutions to treat musculoskeletal patients via Sword Health, which provides a digital therapist, motion sensor device, and personalized treatment plan.

Funding and Financials

The company was launched in 2016 under a joint venture between Verily (a spin-off of Google X’s research group) and drug developer Sanofi, with an initial investment of USD 500 million. However, in December 2019, Sanofi withdrew from the joint venture citing financial concerns.